Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2024-03-19 Capital/Financing Update
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and a subsequent correction (정정신고) to that filing. In the context of Korean financial regulatory filings (DART), these reports detailing capital structure changes, such as bond issuance and conversion terms, are classified as 'Capital/Financing Update' (CAP).
2024-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in Korea. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal share transactions or changes in ownership. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2024-03-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure of insider share transactions, which falls under the 'Director's Dealing' category.
2024-03-18 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Vivozon Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, articles of incorporation changes, and director compensation). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by 'Vivozon Pharmaceutical' regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reasoning for this scheduling conflict and confirms the meeting date. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results of the meeting, it falls under the general regulatory filing category.
2024-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Vivozon Pharmaceutical. It contains the agenda for the meeting, including the approval of financial statements, and provides detailed financial information (balance sheets, income statements, and capital statements) as part of the 'Management Reference' (경영참고사항) required for shareholders to review before the meeting. While it contains financial data, it is not an Annual Report (10-K) but rather a proxy-related document for the AGM. Therefore, it is classified as Proxy Solicitation & Information Statement.
2024-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.